The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders

• Published in: Liver international Vol. 45; no. 6; pp. e70152 - n/a
• Main Authors: Kuo, Meng Hsuan, Tseng, Chih‐Wei, Tseng, Kuo‐Chih, Lu, Ming‐Chi, Tung, Chien‐Hsueh, Chen, Nai‐Tzu, Huang, Kuang‐Yung, Lai, Ning‐Sheng
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2025
• Subjects: Adult; Aged; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Antiviral Agents - therapeutic use; Disease prevention; Etanercept; Female; Hazard assessment; HBV reactivation; Hepatitis B; Hepatitis B Antibodies - blood; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B virus - drug effects; Hepatitis B virus - physiology; Humans; Inhibitors; Male; Middle Aged; Monoclonal antibodies; Prophylaxis; Proportional Hazards Models; Retrospective Studies; Rheumatic diseases; Rheumatic Diseases - drug therapy; rheumatologic patients; Risk Factors; Statistical models; TNF‐α inhibitor potency; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Virus Activation - drug effects; rheumatologic patients; HBV reactivation; TNF‐α inhibitor potency

ABSTRACT Background Rheumatologic patients who test positive for hepatitis B surface antigen (HBsAg) or core antibody (HBcAb) are at risk of HBV reactivation when treated with TNF‐α inhibitors. The effect of TNF‐α inhibitor potency on this risk remains unclear, despite guidelines advising potency‐ba...